References - Translational Medicine in Respiratory Disease

Articles

  • Allarakhia M. Open-source approaches for the repurposing of existing or failed candidate drugs: learning from and applying the lessons across diseases. Drug Design Devel Ther 2013: 7: 753-766.
  • Arrowsmith J, Miller P. Trial watch: phase II and phase III attrition rates 2011-2012. Nat Rev Drug Disc 2013: 12: 569.
  • Barnes PJ. Theophylline. Am J Respir Crit Care Med 2013: 188: 901-906.
  • Bonini S, Eichler H-G, Wathion N, Rasi G. Transparency and the European Medicines Agency--sharing of clinical trial data. N Engl J Med 2014: 371: 2452-2455.
  • Eichler HG, Oye K, Baird LG, Abadie E, Brown J, Drum CL, Ferguson J, Garner S, Honig P, Hukkelhoven M, Lim JCW, Lim R, Lumpkin MM, Neil G, O'Rourke B, Pezalla E, Shoda D, Seyfert-Margolis V, Sigal EV, Sobotka J, Tan D, Unger TF, Hirsch G. Adaptive licensing: taking the next step in the evolution of drug approval. Clin Pharmacol Ther 2012: 91: 426-437.
  • Farré, R., Dinh-Xuan, AT. Translational research in respiratory medicine. ERJ December 1, 2007 vol. 30 no.6: 1041-1042
  • Holmes AM, Solari R, Holgate ST. Animal models of asthma: value, limitations and opportunities for alternative approaches. Drug Discov Today 2011: 16: 659-670.
  • Hörig H, Marincola E, Marincola FM. Obstacles and opportunities in translational Nat Med 2005;11:705–708.
  • Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. Reconstituting organ-level lung functions on a chip. Science 2010: 328;: 1662-1668.
  • Huh D, Leslie DC, Matthews BD, Fraser JP, Jurek S, Hamilton GA, Thorneloe KS, McAlexander MA, Ingber DE. A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Sci Translat Med 2012: 4: 159ra147.
  • Kakkar AK, Dahiya N. Bedaquiline for the treatment of resistant tuberculosis: promises and pitfalls. Tuberculosis 2014: 94: 357-362.
  • Kang L, Chung BG, Langer R, Khademhosseini A. Microfluidics for drug discovery and development: from target selection to product lifecycle management. Drug Disc Today 2008: 13: 1-13.
  • Kobayashi Y, Wada H, Rossios C, Takagi D, Higaki M, Mikura S, Goto H, Barnes PJ, Ito K. A novel macrolide solithromycin exerts superior anti-inflammatory effect via NF-kB inhibition. J Pharmacol Exp Ther 2013: 345: 76-84.
  • Kobayashi Y, Wada H, Rossios C, Takagi D, Charron C, Barnes PJ, Ito K. A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via phosphoinositide 3-kinase pathway inhibition. Br J Pharmacol 2013: 169: 1024-1034.
  • Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug discovery 2004: 3: 711-715.
  • Lincker H, Ziogas C, Carr M, Porta N, Eichler H-G. Regulatory watch: Where do new medicines originate from in the EU? Nat Rev Drug Disc 2014: 13: 92-93.
  • Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012: 380: 2095-2128.
  • Lundblad LK, Barone LM, Murray L. Translational medicine approaches to the study of pulmonary diseases. Pulm Pharmacol Ther. 2011 Apr;24(2):185-6.
  • Maguire TJ, Novik E, Chao P, Barminko J, Nahmias Y, Yarmush ML, Cheng KC. Design and application of microfluidic systems for in vitro pharmacokinetic evaluation of drug candidates. Curr Drug Metab 2009: 10:: 1192-1199.
  • Mercado N, To Y, Ito K, Barnes PJ. Nortriptyline reverses corticosteroid insensitivity by inhibition of PI3K-d. J Pharmacol ExpTher 2011: 337: 465-470.
  • Mercer PF, Abbott-Banner K, Adcock IM, Knowles RG. Translational models of lung disease. Clin Sci (Lond) 2015: 128: 235-256.
  • Migliori GB, Rabe KF, Bel E, Elliott M, Gaga M, Holgate ST, et al. The European Respiratory Society plans its future: the 2013-2018 strategic plan. Eur Respir J. 2014;43:927-32.
  • Morris GE, Bridge JC, Brace LA, Knox AJ, Aylott JW, Brightling CE, Ghaemmaghami AM, Rose FRAJ. A novel electrospun biphasic scaffold provides optimal three-dimensional topography for in vitro co-culture of airway epithelial and fibroblast cells. Biofabrication 2014: 6: 035014-035014.
  • Morris GE, Bridge JC, Eltboli OMI, Knox AJ, Aylott JW, Brightling CE, Ghaemmaghami AM, Rose FRAJ. Human airway smooth muscle maintain in situ cell orientation and phenotype when cultured on aligned electrospun scaffolds. Am J Physiol Lung Cell Mol Physiol 2014: 307: 38-47.
  • Partridge MR, van der Molen T, Myrseth SE, Busse WW. Attitudes and actions of asthma patients on regular maintenance therapy: the INSPIRE study. BMC Pulm Med 2006: 6:13.: 13.
  • Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov 2010: 9: 203-214.
  • Pepys M. Academia Big Pharma collaboration in drug development. Eur Drug Target Rev 2014: 1: 34 - 36.
  • Rasi G. Enabling development of new medicines. Eur Drug Target Rev 2014: 1: 7.
  • Roeder T, Isermann K, Kabesch M. Drosophila in asthma research. Am J Respir Crit Care Med 2009: 179: 979-983.
  • Roeder T, Isermann K, Kallsen K, Uliczka K, Wagner C. A Drosophila asthma model - what the fly tells us about inflammatory diseases of the lung. Adv Exp Med Biol 2012: 710: 37-47.
  • Shaffer TH, Wolfson MR, Shaffer TH. If art imitates life, can laboratory models imitate clinical disease processes?. Crit Care Med 2002; no. 30:2399–2400.
  • Southan C, Williams AJ, Ekins S. Challenges and recommendations for obtaining chemical structures of industry-provided repurposing candidates. Drug Disc Today 2013: 18: 58-70.
  • Sun T, Swindle EJ, Collins JE, Holloway JA, Davies DE, Morgan H. On-chip epithelial barrier function assays using electrical impedance spectroscopy. Lab on a Chip 2010:10: 1611-1617.
  • Swindle EJ, Davies DE. Artificial airways for the study of respiratory disease. Expert Rev Respir Med 2011: 5: 757-765.
  • To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, Elliot M, Hogg JC, Adcock IM, Barnes PJ. Targeting phosphoinositide-3-kinase-d with theophylline reverses corticosteroid insensitivity in COPD. Am J Resp Crit Care Med 2010: 182: 897-904.
  • Tobinick EL. The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 2009: 22: 119-125.
  • Voelkel, Norbert F., Humbert, M. Translational research in pulmonary hypertension: challenge and opportunity. Eur Respir J 2014, no.43: 325-328
  • Wehling M. Assessing the translatability of drug projects: what needs to be scored to predict success? Nat Rev Drug Disc 2009: 8: 541-546.
  • Woolf, S H. The Meaning of Translational Research and Why it Matters. JAMA 2008, January 9/16 – 299, no. 2: 211-213
  • Zimmermann GR, Avery W, Finelli AL, Farwell M, Fraser CC, Borisy AA. Selective amplification of glucocorticoid anti-inflammatory activity through synergistic multi-target action of a combination drug. Arth Res Ther 2009: 11: R12.

Books

  • European Respiratory Society/European Lung Foundation. European Lung White Book. The First Comprehensive Survey on Respiratory Health in Europe. Loddenkemper R, Gibson GJ, Sibille Y, eds. Sheffield, UK, ERSJ, 2003
  • Mestre-Ferrandiz J, Sussex J, Towse A. The R&D cost of a new medicine. Office of Health Economics 2012: 1-86.

Conference proceedings

  • Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehar J, Price ER, Serbedzija G, Zimmermann GR, Foley MA, Stockwell BR, Keith CT. Systematic discovery of multicomponent therapeutics. Proc Nat Acad Sci USA 2003: 100: 7977-7982.
  • Huh D, Fujioka H, Tung Y-C, Futai N, Paine R, Grotberg JB, Takayama S. Acoustically detectable cellular-level lung injury induced by fluid mechanical stresses in microfluidic airway systems. Proc Nat Acad Sci USA 2007: 104: 18886-18891.

Web

 


The ERS Vision film series is made possible through a foundation sponsorship by astrazeneca